Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Starting soon
Conditions studied: Chemotherapy Induced Neuropathic Pain, Neuropathy Toxic, Taxane-induced Peripheral Neuropathy, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients
In brief
The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.
Key facts
- Study ID
- NCT07511569
- Run by
- Centre Hospitalier de Bligny
- People needed
- 192
- Starts
- 2027-01-04
- Expected to finish
- 2029-06-04
- Last updated by the study team
- 2026-04-13
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study
- Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more
- Age > 18 years
- Life expectancy > 3 months
- Patient affiliated with or entitled to social security
You may not qualify if…
- Patients already suffering from neuropathy or chronic neurogenic pain
- Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes)
- Patients who have already received neurotoxic cancer treatment including those in clinical trials
- Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule)
- Patients receiving immunotherapy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.